1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Mar 2022
Admin
News Article

Fda Approves Cancer Therapy By J&J Partner Legend Biotech

"This Is The First Of Many Cell Therapies We Plan To Bring To Patients As We Continue Advancing Our Pipeline Across Disease States," Said Ying Huang, Legend'S Chief Executive Officer And Chief Financial Officer. The U.S. Health Regulator Has Approved A Therapy Developed By Johnson & Johnson And Its China-Focused Partner Legend Biotech Corp To Treat A Type Of White Blood Cell Cancer, The U.S. Healthcare Company Said On Monday. The Food And Drug Administration'S Decision Paves The Way For Legend'S First Approved Product In The United States, At A Time When The Regulator Has Stepped Up Its Scrutiny Of Drug Trials Conducted In China. The Legend-J&J Therapy Was Tested Initially In China, And Then In The United States And Japan. "This Is The First Of Many Cell Therapies We Plan To Bring To Patients As We Continue Advancing Our Pipeline Across Disease States," Said Ying Huang, Legend'S Chief Executive Officer And Chief Financial Officer. The Treatment, Carvykti/Cilta-Cel, Belongs To A Class Of Drugs Known As Car-T Therapies, Or Chimeric Antigen Receptor T-Cell Therapies. Car-T Drugs Work By Harvesting A Patient'S Own Disease-Fighting T-Cells, Genetically Engineering Them To Target Specific Proteins On Cancer Cells, And Replacing Them To Seek Out And Attack Cancer. Legend And J&J Will Sell The Drug In Greater China At 70-30 Split In Profit, And In All Other Countries In A 50-50 Split In Profit. Https://Bit.Ly/3C1Cfns A Decision On The Car-T Therapy Was Initially Expected To Come By The End Of November After It Was Given Priority Review Six Months Earlier, But This Was Extended By Three Months To Allow Sufficient Time To Review Information Submitted By J&J Following An Fda Request. Legend, Which Initiated The Development, Signed An Agreement With Janssen Biotech Inc, An Arm Of J&J, In 2017, To Jointly Develop And Commercialize The Drug, With Legend Getting $350 Million In Upfront Payment. Besides The United States, Carvykti/Cilta-Cel Is Also Being Reviewed By Health Authorities In Japan And Europe. A Marketing Authorisation Application (Maa) For The Therapy In China Is Yet To Be Filed

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!